Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us ![]()
About
Not Confirmed
Not Confirmed
03-07 May, 2026
Not Confirmed
Not Confirmed
04-07 May, 2026
Vitafoods EuropeVitafoods Europe
Not Confirmed
Not Confirmed
05-07 May, 2026
List your booth number for exhibitions, ask us
CONTACT DETAILS






Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
Industry Trade Show
Not Confirmed
03-07 May, 2026
Industry Trade Show
Not Confirmed
04-07 May, 2026
Vitafoods EuropeVitafoods Europe
Industry Trade Show
Not Confirmed
05-07 May, 2026
Digital content

28 Apr 2026
// FIRSTWORD PHARMA

16 Apr 2026
// FIRSTWORD PHARMA

13 Apr 2026
// GLOBENEWSWIRE
https://www.globenewswire.com/news-release/2026/04/13/3272888/0/en/Sana-Biotechnology-and-Mayo-Clinic-Announce-Strategic-Collaboration-Focused-on-Improving-Care-in-Type-1-Diabetes-and-Accelerating-Development-of-SC451.html

10 Apr 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/pendulum-therapeutics-expands-clinical-collaboration-to-advance-microbiome-research-in-womens-health-and-dermatology-302739314.html

25 Mar 2026
// FIERCE BIOTECH
https://www.fiercebiotech.com/medtech/endogenex-nets-50m-carry-intestinal-diabetes-procedure-fda

24 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/anti-aging-protein-research-takes-a-step-forward-with-cell-cloning-302723584.html
Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Tavneos (Avacopan) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of diffuse alveolar hemorrhage.
Lead Product(s): Avacopan
Therapeutic Area: Pulmonary/Respiratory Diseases Brand Name: Tavneos
Study Phase: Phase IProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 29, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Avacopan
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics Of Emulsified Avacopan Applied By NG Tube
Details : Tavneos (Avacopan) is a small molecule drug, which is currently being evaluated in Phase I clinical studies for the treatment of diffuse alveolar hemorrhage.
Product Name : Tavneos
Product Type : Miscellaneous
Upfront Cash : Inapplicable
April 29, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
The collaboration aims to advance cell & gene therapy for type 1 diabetes with lead product SC451.
Lead Product(s): SC451
Therapeutic Area: Endocrinology Brand Name: Undisclosed
Study Phase: PreclinicalProduct Type: Cell & Gene Therapy
Recipient: Sana Biotechnology
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration April 13, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : SC451
Therapeutic Area : Endocrinology
Highest Development Status : Preclinical
Recipient : Sana Biotechnology
Deal Size : Undisclosed
Deal Type : Collaboration
Sana Biotechnology, Mayo Clinic Collaborate on Type 1 Diabetes Care, SC451 Development
Details : The collaboration aims to advance cell & gene therapy for type 1 diabetes with lead product SC451.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Undisclosed
April 13, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Ipilimumab is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of carcinoma, renal cell.
Lead Product(s): Ipilimumab,Nivolumab,VSV-IFNβ-NIS
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 03, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Ipilimumab,Nivolumab,VSV-IFNβ-NIS
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
VSV-IFNβ-NIS With Ipilimumab and Nivolumab for the Treatment of Advanced or Metastatic Clear Cell...
Details : Ipilimumab is a antibody drug, which is currently being evaluated in Phase II clinical studies for the treatment of carcinoma, renal cell.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 03, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Bimekizumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pityriasis Rubra Pilaris.
Lead Product(s): Bimekizumab
Therapeutic Area: Dermatology Brand Name: Undisclosed
Study Phase: Phase IVProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 27, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Bimekizumab
Therapeutic Area : Dermatology
Highest Development Status : Phase IV
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Bimzelx (Bimekizumab) For The Treatment Of Adult Onset PRP
Details : Bimekizumab is a Antibody, Unconjugated drug candidate, which is currently being evaluated in Phase IV clinical studies for the treatment of Pityriasis Rubra Pilaris.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 27, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Nicotine is a Miscellaneous drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Smoking Cessation.
Lead Product(s): Nicotine
Therapeutic Area: Psychiatry/Psychology Brand Name: Undisclosed
Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous
Sponsor: National Cancer Institute
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 23, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Nicotine
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Partner/Sponsor/Collaborator : National Cancer Institute
Deal Size : Inapplicable
Deal Type : Inapplicable
A Study Of Vagal Nerve Stimulation In Conjunction With NRT For Smoking Cessation
Details : Nicotine is a Miscellaneous drug candidate, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of Smoking Cessation.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 23, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Spironolactone is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of aortic aneurysm, thoracic.
Lead Product(s): Spironolactone
Therapeutic Area: Cardiology/Vascular Diseases Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 19, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Spironolactone
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
HEART: Pilot Randomized Controlled Trial
Details : Spironolactone is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of aortic aneurysm, thoracic.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 19, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Retifanlimab is a antibody drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of oligodendroglioma.
Lead Product(s): Retifanlimab,Eflornithine Hydrochloride
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Retifanlimab,Eflornithine Hydrochloride
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Retifanlimab is a antibody drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of oligodendroglioma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 12, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Zoladex (Goserelin Acetate) is a peptide drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Lead Product(s): Goserelin Acetate
Therapeutic Area: Oncology Brand Name: Zoladex
Study Phase: Phase IIProduct Type: Peptide, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 10, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Goserelin Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Zoladex (Goserelin Acetate) is a peptide drug, which is currently being evaluated in Phase II clinical studies for the treatment of breast neoplasms.
Product Name : Zoladex
Product Type : Peptide, Unconjugated
Upfront Cash : Inapplicable
March 10, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
Imdur (Isosorbide Mononitrate) is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of digestive system neoplasms.
Lead Product(s): Isosorbide Mononitrate,Diltiazem Hydrochloride,Fluorouracil,Capecitabine
Therapeutic Area: Oncology Brand Name: Imdur
Study Phase: Phase I/ Phase IIProduct Type: Miscellaneous
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Isosorbide Mononitrate,Diltiazem Hydrochloride,Fluorouracil,Capecitabine
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Imdur (Isosorbide Mononitrate) is a small molecule drug, which is currently being evaluated in Phase I/ Phase II clinical studies for the treatment of digestive system neoplasms.
Product Name : Imdur
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Details:
18-F Fluoroethyl-L-Tyrosine is a radiolabeled compound drug, which is currently being evaluated in Phase I clinical studies for the treatment of pituitary neoplasms.
Lead Product(s): 18-F Fluoroethyl-L-Tyrosine
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Radiolabeled Compound
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 09, 2026

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : 18-F Fluoroethyl-L-Tyrosine
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Use of [18F] Fluoroethyl-L-tyrosine PET/MRI for Identifying Small Functional Pituitary Adenomas
Details : 18-F Fluoroethyl-L-Tyrosine is a radiolabeled compound drug, which is currently being evaluated in Phase I clinical studies for the treatment of pituitary neoplasms.
Product Name : Undisclosed
Product Type : Radiolabeled Compound
Upfront Cash : Inapplicable
March 09, 2026

FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]ABOUT THIS PAGE
Mayo Clinic is a supplier offers 3 products (APIs, Excipients or Intermediates).
Find Ribavirin bulk offered by Mayo Clinic
Find COMMITTEE ON SAFETY OF THERAPEUTIC AGENTS bulk offered by Mayo Clinic
Find HUMAN GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR (IMMUNEX), AEROSOL bulk offered by Mayo Clinic